In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...
(Reuters) - Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China ...
11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...
(Reuters) - Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow ...